JP2018523980A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523980A5
JP2018523980A5 JP2017564467A JP2017564467A JP2018523980A5 JP 2018523980 A5 JP2018523980 A5 JP 2018523980A5 JP 2017564467 A JP2017564467 A JP 2017564467A JP 2017564467 A JP2017564467 A JP 2017564467A JP 2018523980 A5 JP2018523980 A5 JP 2018523980A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
seq
polypeptide
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017564467A
Other languages
English (en)
Japanese (ja)
Other versions
JP6873054B2 (ja
JP2018523980A (ja
Filing date
Publication date
Priority claimed from GBGB1510357.5A external-priority patent/GB201510357D0/en
Priority claimed from PCT/EP2015/063248 external-priority patent/WO2015189425A1/en
Priority claimed from GBGB1514772.1A external-priority patent/GB201514772D0/en
Application filed filed Critical
Priority claimed from PCT/EP2016/063329 external-priority patent/WO2016198621A1/en
Publication of JP2018523980A publication Critical patent/JP2018523980A/ja
Publication of JP2018523980A5 publication Critical patent/JP2018523980A5/ja
Application granted granted Critical
Publication of JP6873054B2 publication Critical patent/JP6873054B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017564467A 2015-06-12 2016-06-10 アデノウイルスポリヌクレオチド及びポリペプチド Active JP6873054B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1510357.5A GB201510357D0 (en) 2015-06-12 2015-06-12 Adenovirus polynucleotides and polypeptides
EPPCT/EP2015/063248 2015-06-12
PCT/EP2015/063248 WO2015189425A1 (en) 2014-06-13 2015-06-12 Immunogenic combinations
GB1510357.5 2015-06-12
GBGB1514772.1A GB201514772D0 (en) 2015-08-19 2015-08-19 Adenovirus polynucleotides and polypeptides
GB1514772.1 2015-08-19
PCT/EP2016/063329 WO2016198621A1 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides

Publications (3)

Publication Number Publication Date
JP2018523980A JP2018523980A (ja) 2018-08-30
JP2018523980A5 true JP2018523980A5 (https=) 2018-11-01
JP6873054B2 JP6873054B2 (ja) 2021-05-19

Family

ID=57503533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017564424A Expired - Fee Related JP6983665B2 (ja) 2015-06-12 2016-06-10 アデノウイルスポリヌクレオチド及びポリペプチド
JP2017564467A Active JP6873054B2 (ja) 2015-06-12 2016-06-10 アデノウイルスポリヌクレオチド及びポリペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017564424A Expired - Fee Related JP6983665B2 (ja) 2015-06-12 2016-06-10 アデノウイルスポリヌクレオチド及びポリペプチド

Country Status (13)

Country Link
US (4) US11254710B2 (https=)
EP (2) EP3307313A1 (https=)
JP (2) JP6983665B2 (https=)
KR (2) KR20180012857A (https=)
CN (2) CN108025058B (https=)
AU (4) AU2016275601A1 (https=)
BE (1) BE1024420B1 (https=)
BR (1) BR112017026523A2 (https=)
CA (1) CA2988654A1 (https=)
EA (1) EA038402B9 (https=)
IL (2) IL256069B2 (https=)
MX (2) MX2017016101A (https=)
WO (2) WO2016198621A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026523A2 (pt) 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
ES2959811T3 (es) * 2016-12-09 2024-02-28 Glaxosmithkline Biologicals Sa Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus
WO2019016756A1 (en) 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
EP3697902A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals S.A. Enhanced promoter
JP2021500880A (ja) 2017-10-16 2021-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 2つの発現カセットを有するサルアデノウイルスベクター
WO2019076877A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ADENOVIRAL VECTORS FOR REPLICATION
EP3697919A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals SA Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
WO2019086466A1 (en) * 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
BR112020012361A2 (pt) * 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
EP3807298A1 (en) 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Adenovirus polynucleotides and polypeptides
US20210277417A1 (en) * 2018-06-25 2021-09-09 Akouos, Inc. Methods of treating clrn1-associated hearing loss and/or vision loss
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
EP3810277A1 (en) * 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
EP4150344A1 (en) 2020-05-14 2023-03-22 GlaxoSmithKline Biologicals SA Viral biosensors
CN121816424A (zh) * 2023-08-11 2026-04-07 拜奥卡德联合股份公司 用于生产基于腺相关病毒(AAV)的载体(变体)的腺病毒E2a基因的修饰的序列

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
KR20040043129A (ko) 2001-06-22 2004-05-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 세포독성 면역 반응을 유도하는 방법과 그에 유용한재조합체 원숭이 아데노바이러스 조성물
AU2002365366B2 (en) * 2001-11-21 2007-05-10 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7030094B2 (en) 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7205342B2 (en) * 2003-10-10 2007-04-17 General Electric Company Poly(arylene ether) composition and method of molding
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
EP2848692B1 (en) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
CN102220357B (zh) * 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
AR053275A1 (es) * 2005-05-12 2007-04-25 Glaxo Group Ltd Composicion de vacuna
WO2006133911A2 (en) * 2005-06-17 2006-12-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hepatitis c virus nucleic acid vaccine
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
AU2008331905B2 (en) * 2007-11-28 2014-09-18 The Trustees Of The University Of Pennsylvania Simian subfamily B adenovirus SAdV-28 and uses thereof
CN102131920B (zh) * 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
CN101883858B (zh) * 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
JP5661476B2 (ja) * 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
PL2391638T3 (pl) * 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
CA2762203A1 (en) * 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
JP5903045B2 (ja) * 2009-07-31 2016-04-13 パックスバックス, インコーポレイテッド アデノウイルスに基づくベクター
US9526777B2 (en) * 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US20120328605A1 (en) 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
FR2978457A1 (fr) * 2011-07-27 2013-02-01 Univ Paris Diderot Paris 7 Composes contenant un vecteur viral a specificite hepatique et presentant une activite anti-inflammatoire
US9233153B2 (en) * 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Rsvに対するワクチン
KR102435054B1 (ko) 2012-08-01 2022-08-22 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
DE102012221236A1 (de) 2012-11-21 2014-05-22 Zf Friedrichshafen Ag Getriebe
GB201303406D0 (en) * 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
CN103937835A (zh) * 2013-08-19 2014-07-23 中国科学院上海巴斯德研究所 一种基于腺病毒AdC68的表达载体及其构建方法
CN103923943B (zh) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 一种基于腺病毒AdC7的表达载体及其构建方法
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
BR112017026523A2 (pt) 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.

Similar Documents

Publication Publication Date Title
JP2018523980A5 (https=)
JP2015057052A5 (https=)
JP2020511940A5 (https=)
JP2018524977A5 (https=)
JP2012516679A5 (https=)
Vrati et al. Unique genome arrangement of an ovine adenovirus: identification of new proteins and proteinase cleavage sites
JP6970647B2 (ja) シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP6970059B2 (ja) アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法
CN111108192B (zh) 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途
JP2020511114A5 (https=)
RU2011136282A (ru) Нуклеинокислотные и аминокислотные последовательности аденовируса обезьян, векторы, содержащие указанные последовательности, и их применение
US9133248B2 (en) Methods of propagating monkey adenoviral vectors
JP2014516536A5 (https=)
US20210269827A1 (en) Modified serotype 28 adenoviral vectors
US6844192B2 (en) Adenovirus E4 protein variants for virus production
Shenk Group C adenoviruses as vectors for gene therapy
Baxi et al. Mutational analysis of early region 4 of bovine adenovirus type 3
JP2009535031A5 (https=)
US7687615B2 (en) PAV regions for encapsidation and E1 transcriptional control
CN101363028A (zh) 互补型高容量腺病毒载体系统及其构建的疫苗和基因治疗产品
Zeng et al. Genomic organization of EDSV strain AA-2
US20110135688A1 (en) Methods and Compositions for Increasing Titer of Recombinant Porcine Adenovirus-3 Vectors
Garceac Sequence comparison of the right end of fowl adenovirus genomes
HK40031047A (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
HK40031047B (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof